Actively Recruiting
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Led by Yonsei University · Updated on 2023-01-31
3000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Genitourinary cancers such as prostate cancer, renal cell cancer, bladder cancer, and ureter cancer have been increasing in the Korean population due to aging and lifestyle changes. Researchers are studying how the microbiome in tissues, blood plasma, stool, and urine may help detect these cancers, monitor disease progression, and evaluate treatment responses. This observational study aims to build a large database of the microbiome related to urological malignancies in Korean patients. The study collects samples from patients who have been diagnosed with urological cancers and have undergone surgeries such as prostatectomy, nephrectomy, cystectomy, or ureterectomy. Samples include tissue, plasma, stool, and urine collected within two weeks after surgery. The study will analyze the composition of bacteria in these samples and correlate them with the presence of cancer and tumor response over up to 10 years. Participants provide permission to use their biological samples and medical information for this research. Researchers will assess bacterial composition and its correlation with cancer prevalence shortly after surgery and track tumor response using standardized criteria for up to ten years. The study involves long-term monitoring and data collection to support personalized medicine approaches for urological cancers in Korea.
CONDITIONS
Brief Title
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with urological malignancies including prostate cancer, renal cell cancer, bladder cancer, and ureter cancer
- Patients who have undergone surgeries for these cancers at Severance Hospital between October 2020 and October 2030
- Patients who agree to allow use of their biological samples and medical information for research
- Patients who consent to participate in this study
You will not qualify if you...
- Patients who do not agree to participate in this study
- Vulnerable individuals who may be at risk of coercion or undue influence or lack the ability to make decisions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Within 2 weeks after the surgery
Participants provide biological samples including tissue, plasma, stool, and urine to analyze bacteria composition related to urological malignancies.
1 to 2 visits depending on sample type
Duration - Up to 10 years after the surgery
Participants are followed for up to 10 years to assess tumor response and correlate it with bacteria composition.
Periodic assessments during follow-up
Trial Site Locations
Total: 1 location
1
Yonsei Severance Hospital
Seoul, South Korea
Actively Recruiting
Research Team
W
Won Sik Ham
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here